3,766,358 Equity Shares of Alkem Laboratories Limited are subject to a Lock-Up Agreement Ending on 17-JAN-2016.
January 17, 2016
Share
3,766,358 Equity Shares of Alkem Laboratories Limited are subject to a Lock-Up Agreement Ending on 17-JAN-2016. These Equity Shares will be under lockup for 29 days starting from 19-DEC-2015 to 17-JAN-2016.
Details:
The promoters of the company have agreed not to dispose of an aggregate of 23,913,002 shares of the company for a period of three years from the date of allotment of the offer shares in the issue, December 19, 2015.
The entire remaining pre-issue equity share capital of the company consisting of 82,798,556 shares, will be locked-in for a period of one year from the date of allotment in the issue.
An aggregate of 3,766,358 shares will be under lock-up for 30 days from the allotment date.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
ALKEM LABORATORIES LIMITED 
